fda warning letter glp-1 october 2025 Beyond the Headlines: Letters to Compounders FDA seeks changes to GLP-1,

In addition, subjects on VYVANSE showed greater improvement as compared to placebo across key secondary outcomes with higher proportion of subjects rated improved on the CGI-I rating scale, higher proportion of subjects with 4-week binge cessation, and greater reduction in the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) total score

They can figure out if the symptoms are from the medication or something else

Start with a licensed provider who reviews your health history, goals, and labs, then builds a medically supervised weight loss plan quoted at consultation

Alternative Treatments If Nausea Persists If nausea remains problematic despite dose adjustments and supportive measures, several options exist